MRVI
Maravai
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
Consensus Rating "Strong Buy"
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MRVI
Maravai Lifesciences Holdings, Inc.
A leading life sciences company that provides products to develop drug therapies, diagnostics, novel vaccines, and supports research on diseases
10770 Wateridge Circle Suite 200, San Diego, California 92121
--
Maravai Lifesciences Holdings, Inc., was incorporated in Delaware on August 25, 2020. The company is a leading life sciences company that provides key products to support drug therapies, diagnostics, development of novel vaccines, and supporting research in human diseases.
Earnings Call
Q1/2025
Estimate EPS-0.07
Actual EPS-0.08
Estimate Revenue44.01M
Actual Revenue46.90M
Maravai's Q1 2025: Contradictions in Pipeline Focus, Revenue Seasonality, and Manufacturing Strategies
May 20,2025 06:30
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MRVI has released its 2025 Q1 earnings. EPS was reported at -0.08, versus the expected -0.07, missing expectations. The chart below visualizes how MRVI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRVI has released its 2025 Q1 earnings report, with revenue of 46.85M, reflecting a YoY change of -27.00%, and net profit of -52.85M, showing a YoY change of -133.04%. The Sankey diagram below clearly presents MRVI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
